<DOC>
	<DOCNO>NCT02837042</DOCNO>
	<brief_summary>Penile squamous cell carcinoma ( PSCC ) relatively rare exhibit higher incidence less developed country . PSCC highly aggressive malignancy characterize early spread . Pembrolizumab recently FDA-approved treatment melanoma serve investigational agent penile cancer study .</brief_summary>
	<brief_title>Trial Pembrolizumab Advanced Penile Squamous Cell Carcinoma</brief_title>
	<detailed_description>This multicenter trial evaluate Pembrolizumab patient advance penile squamous cell carcinoma follow prior chemotherapy . Participating institution University Alabama Birmingham ( coordinate center ) , M.D . Anderson Cancer Center , University Michigan , University Minnesota , Emory University . Patients receive intravenous Pembrolizumab every 3 week undergo clinical exam . Radiographic scan do baseline every 9 week . Therapy continue disease progression intolerable toxicity .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>1 . Locally advanced unresectable metastatic stage 4 ( i.e . T4 N3 M1 ) PSCC 2 . Radiologic evidence progressive disease ≥1 prior chemotherapy regimen 3 . Be least 18 year age day sign informed consent . 4 . Have measurable disease base RECIST 1.1 . 5 . Have performance status 02 ECOG ( Eastern Cooperative Oncology Group ) Performance Scale . 6 . Demonstrate adequate organ function screen lab perform within 14 day treatment initiation . Absolute neutrophil count ( ANC ) ≥1,500 /mcL Platelets ≥100,000/mcL Hemoglobin ≥9 g/dL ≥5.6 mmol/L without transfusion erythropoietin dependency ( within 7 day assessment ) Serum creatinine ≤1.5 X upper limit normal ( ULN ) ; alternately measure calculated creatinine clearance ≥30 mL/min creatinine level &gt; 1.5 X institutional ULN ( GFR also use place creatinine CrCl ) Serum total bilirubin ≤1.5 X ULN direct bilirubin ≤ ULN subject total bilirubin level &gt; 1.5 ULN AST ( SGOT ) ALT ( SGPT ) ≤ 2.5 X ULN ≤ 5 X ULN subject liver metastasis Albumin &gt; 2.5 mg/dL International Normalized Ratio ( INR ) Prothrombin Time ( PT ) ≤1.5 X ULN unless subject receive anticoagulant therapy long PT PTT within therapeutic range intend use anticoagulant Activated Partial Thromboplastin Time ( aPTT ) ≤1.5 X ULN unless subject receive anticoagulant therapy long PT PTT within therapeutic range intend use anticoagulant 7 . Subjects agree use adequate method contraception start first dose study therapy 120 day last dose study therapy 8 . Formalinfixed paraffin embed ( FFPE ) tumor tissue previous biopsy request , mandatory . 9 . Be willing able provide write informed consent/assent trial . 1 . Is currently participate receive study therapy participate study investigational agent receive study therapy use investigational device within 4 week first dose treatment . 2 . Has diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose trial treatment . 3 . Has know history active TB ( Bacillus Tuberculosis ) 4 . Hypersensitivity Pembrolizumab excipients . 5 . Has prior anticancer monoclonal antibody ( mAb ) within 4 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due agent administer 4 week earlier . 6 . Has prior chemotherapy , target small molecule therapy , radiation therapy within 2 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due previously administer agent . Note : Subjects ≤ Grade 2 neuropathy exception criterion may qualify study . Note : If subject receive major surgery , must recover adequately toxicity and/or complication intervention prior start therapy . 7 . Has know additional malignancy progress require active treatment . Exceptions include basal cell carcinoma skin squamous cell carcinoma skin undergone potentially curative therapy situ cervical cancer . 8 . Has know active central nervous system ( CNS ) metastases and/or carcinomatous meningitis . Subjects previously treat brain metastasis may participate provide stable ( without evidence progression image least four week prior first dose trial treatment neurologic symptom return baseline ) , evidence new enlarge brain metastasis , use steroid least 7 day prior trial treatment . This exception include carcinomatous meningitis exclude regardless clinical stability . 9 . Has active autoimmune disease require systemic treatment past 2 year ( i.e . use disease modify agent , corticosteroid immunosuppressive drug ) . Replacement therapy ( e.g . thyroxine , insulin , physiologic corticosteroid replacement therapy adrenal pituitary insufficiency , etc . ) consider form systemic treatment . 10 . Has know history , evidence active , noninfectious pneumonitis . 11 . Has active infection require systemic therapy . 12 . Has history current evidence condition , therapy , laboratory abnormality might confound result trial , interfere subject 's participation full duration trial , best interest subject participate , opinion treat investigator . 13 . Has know psychiatric substance abuse disorder would interfere cooperation requirement trial . 14 . Is pregnant expect father child within project duration trial , start prescreening screen visit 120 day last dose trial treatment . 15 . Has receive prior therapy antiPD1 , antiPDL1 , antiPDL2 agent . 16 . Has know history Human Immunodeficiency Virus ( HIV ) ( HIV 1/2 antibody ) . 17 . Has know active Hepatitis B ( e.g. , HBsAg reactive ) Hepatitis C ( e.g. , HCV RNA [ qualitative ] detect ) . 18 . Has know active Tuberculosis infection . 19 . Has receive live vaccine within 30 day plan start study therapy . Note : Seasonal influenza vaccine injection generally inactivate flu vaccine allow ; however intranasal influenza vaccine ( e.g. , FluMist® ) live attenuate vaccine , allow .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>penile cancer</keyword>
	<keyword>Pembrolizumab</keyword>
	<keyword>penile squamous cell carcinoma</keyword>
	<keyword>squamous cell cancer</keyword>
</DOC>